Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

NERx BioSciences Inc
Profile last edited on: 12/5/19      CAGE: 668Y4      UEI: PZ6HDAKNKXY9

Business Identifier: Targeted therapeutics for cancer.
Year Founded
2009
First Award
2012
Latest Award
2017
Program Status
Inactive
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

212 West 10th Street Suite A480
Indianapolis, IN 46202
   (317) 612-4672
   info@nerxbiosciences.com
   www.nerxbiosciences.com
Location: Single
Congr. District: 07
County: Marion

Public Profile

NERx BioSciences Inc is a biotechnology company working to discover and develop targeted therapeutics for cancer. NERx specializes in the discovery and early development of novel biopharmaceutical compounds, with a specific focus having been placed on a new generation of cancer drugs targeting specific cellular processes but that are not currently being exploited as cancer therapies. With NERx's approach ibeing to use SMIs to approach the nucleotide exision repair pathway. the company' research comes primarily from its own lab but the firm is receptive to acquisition of orphan IP. N

Extent of SBIR involvement

User Avatar
Phase I Awards
5
Phase II Awards
0
Conversion Rate
0.00%
Phase I Dollars
$1,372,038
Phase II Dollars
$181,091
Total Awarded
$1,553,129

Synopsis: Awardee Business Condition

Employee Range
10-14
Revenue Range
1M-1.5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2017 1 NIH $300,000
Project Title: Development of novel Ku targeted kinase inhibitors
2017 1 NIH $299,275
Project Title: Development of Novel Lung Cancer Therapeutics Targeting the Dna Damage Response
2016 1 NIH $293,005
Project Title: Chemical enhancement of CRISPR/Cas9 mediated site-specific genome engineering
2013 1 NIH $360,927
Project Title: Development of Novel Agents Targeting Genome Stability and Maintenance for Treati
2012 1 NIH $299,922
Project Title: Targeting The Ercc1/Xpf Nuclease For Cancer Therapy

Key People / Management

  John J Turchi -- Co-Founder, President and Chief Scientific Officer

  Nick Ball -- VP Finance

  Lawrence Einhorn -- Chair Scientific/Medical Advisory Board

  Robert Feltgen -- Co-Founder

  Rebecca LaFlamme

  Micah Mackison

  Katherine Pawelczak -- VP Research

Company News

There are no news available.